Pharmafile Logo
Pharmafocus logo
Advanced Search

Revlimid

Showing 15 posts of 27 posts found.

450px-flag_of_scotland

Scottish Medicines Consortium approves Revlimid for two groups of blood cancer patients

October 14, 2020
Research and Development Revlimid, SMC

The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland for patients with multiple myeloma …

News

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

September 11, 2020
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance of newly diagnosed multiple myeloma …

News
celgene_building

NICE recommends Celgene’s Revlimid combo for follicular lymphoma

February 27, 2020
Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …

News
celgene_building

FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma

May 29, 2019
Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …

News
celgene_building

NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma

May 20, 2019
Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma

Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …

News
celgene_building

Celgene’s Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma

July 24, 2018
Manufacturing and Production, Research and Development Celgene, Revlimid, lymphoma, pharma

Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in …

News
celgene_exteriors-3

Celgene hikes price of Revlimid to mask poor Q3 results

October 27, 2017
Medical Communications, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical

Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut …

News

Celgene agrees one of the largest settlements for false claims on record

July 26, 2017
Research and Development, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical, thalomid

It has been announced that Celgene has agreed to settle a case after a whistle-blower launched a lawsuit against the …

News
revlimid_celgene

Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU

January 27, 2017
Sales and Marketing Celgene, Revlimid, multiple myeloma

Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …

News
celgene_1_02

NICE rejects Celegene’s Revlimid as second-line treatment

November 16, 2016
Research and Development, Sales and Marketing Celegene, Revlimid

NICE has decided Celegene’s multiple myeloma growth engine Revlimid (lenalidomide) will not be offered to patients as a second line …

News
celgene_1_02

Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial

July 26, 2016
Research and Development Celgene, Revlimid, lymphoma

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …

News
celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016
Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 

News
celgene_1_02

Two Celgene cancer drugs approved in Ireland

March 1, 2016
Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid

Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …

News
Celgene logo

Celgene settles Revlimid patent dispute

December 23, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Celgene, India, Natco, Revlimid, lenalidomide, patents

Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …

News
Keytruda image

MSD’s Keytruda shows promise in multiple myeloma

December 7, 2015
Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab

MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023